# Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

> **NCT01720264** · PHASE2 · COMPLETED · sponsor: **Sherif S. Farag** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Hematopoetic Myelodysplasia
- Leukemia, Myelogenous, Chronic
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01720264
- **Lead sponsor:** Sherif S. Farag
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-02
- **Primary completion:** 2016-08-27
- **Final completion:** 2017-12-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720264, "Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01720264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*